41 research outputs found
Improvements in population-based survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, 1992â2008
We analysed population-based treatment and survival data of patients who presented with metastatic rectal cancer. All patients diagnosed with primary synchronous metastatic rectal cancer between 1992 and 2008 in the Eindhoven Cancer Registry area were included. Date of diagnosis was divided into three periods (1992â1999, 2000â2004, 2005â2008) according to the availability of chemotherapy type. We assessed treatment patterns and overall survival according to period of diagnosis. The proportion of patients diagnosed with stage IV disease increased from 16% in 1992â1999 to 20% in 2005â2008 (PÂ <Â 0.0001). Chemotherapy use increased from 5% in 1992 to 61% in 2008 (PÂ <Â 0.0001). Resection rates of the primary tumour decreased from 65% in 1992 to 27% in 2008 (PÂ <Â 0.0001), while metastasectomy rates remained constant since 1999 (9%). Median survival increased from 38Â weeks (95% confidence interval (CI) 32â44) in 1992â1999 to 53Â weeks (95% CI 48â61) in 2005â2008. Among patients not receiving chemotherapy median survival remained approximately 30Â weeks. Multivariable analysis confirmed the lower risk of death among patients diagnosed in more recent years. Increased use of chemotherapy went together with improved median survival among patients with metastatic rectal cancer in the last two decades. Stage migration as an effect of more effective imaging procedures is likely to be partly responsible for this improved survival
Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
Investigation of chemical transformations of thiophenylglycoside of muramyl dipeptide on the fumed silica surface using TPD-MS, FTIR spectroscopy and ES IT MS
Drug discovery in advanced prostate cancer: translating biology into therapy.
Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses considerable therapeutic challenges. Recent genetic and technological advances have provided insights into prostate cancer biology and have enabled the identification of novel drug targets and potent molecularly targeted therapeutics for this disease. In this article, we review recent advances in prostate cancer target identification for drug discovery and discuss their promise and associated challenges. We review the evolving therapeutic landscape of CRPC and discuss issues associated with precision medicine as well as challenges encountered with immunotherapy for this disease. Finally, we envision the future management of CRPC, highlighting the use of circulating biomarkers and modern clinical trial designs